Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 126 от 154

Активно (без набиране)

REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

Benign Prostatic Hyperplasia (BPH)

The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.

Начало: 15.09.2021 Край: 01.03.2027 Възраст: от 45 г. Лечение

Australia, France Boston Scientific Corporation NCT04838769

Активно (без набиране) Фаза 3

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis

The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.

Начало: 15.09.2021 Край: 01.09.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Czechia +11 Bristol-Myers Squibb NCT04909801

Активно (без набиране) Фаза 1/2

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Carcinoma

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Начало: 14.09.2021 Край: 01.06.2028 Възраст: 18–130 г. Лечение

Australia, Belgium, Brazil +13 AstraZeneca NCT04995523

Активно (без набиране) Фаза 3

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma Botryoid-Type Embryonal Rhabdomyosarcoma Embryonal Rhabdomyosarcoma Metastatic Embryonal Rhabdomyosarcoma +4

This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body. This study will also examine if adding maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in a class of medications called vinca alkaloids. They work by stopping cancer cells from growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only used in cancer chemotherapy. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are chemotherapy medications that work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or for the rest of patient's life.

Начало: 14.09.2021 Край: 30.06.2026 Възраст: до 50 г. Лечение

Australia, Canada, Puerto Rico +2 Children's Oncology Group NCT04994132

Активно (без набиране) Фаза 3

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Renal Cell Carcinoma

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

Начало: 09.09.2021 Край: 30.12.2025 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +12 AVEO Pharmaceuticals, Inc. NCT04987203

Активно (без набиране) Фаза 2

Hepatocellular Carcinoma Imaging Using PSMA PET/CT

Hepatocellular Carcinoma

The purpose of the research is to evaluate the use of a PSMA PET/CT (Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography) scan in the diagnosis of HCC (hepatocellular carcinoma) and comparing it to standard scanning techniques with CT (Computed Tomography) or MRI (Magnetic Resonance Imaging).

Начало: 08.09.2021 Край: 08.09.2026 Възраст: от 18 г. Диагностика

Australia Peter MacCallum Cancer Centre, Australia NCT05095519

Активно (без набиране) Фаза 3

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

Cardiovascular Risk Chronic Kidney Disease Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits. Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Начало: 30.08.2021 Край: 09.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +33 Novo Nordisk A/S NCT05021835

Активно (без набиране) Фаза 4

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Arthritis, Psoriatic

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

Начало: 30.08.2021 Край: 13.04.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Bulgaria +21 Janssen Research & Development, LLC NCT04929210

Активно (без набиране) Фаза 3

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Начало: 27.08.2021 Край: 01.01.2035 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +46 Hoffmann-La Roche NCT04961996

Активно (без набиране)

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

Arthritis, Psoriatic

The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).

Начало: 25.08.2021 Край: 02.08.2027 Възраст: от 18 г.

Argentina, Australia, Belgium +15 Janssen Pharmaceutica N.V., Belgium NCT05049798

Активно (без набиране) Фаза 3

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Multiple Myeloma

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).

Начало: 19.08.2021 Край: 22.09.2036 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 Janssen Research & Development, LLC NCT04923893

Активно (без набиране) Фаза 3

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NASH - Nonalcoholic Steatohepatitis

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Начало: 19.08.2021 Край: 30.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Inventiva Pharma NCT04849728

Активно (без набиране) Фаза 2

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Neoplasm Malignant

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.

Начало: 18.08.2021 Край: 22.03.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Chile +7 Merck Sharp & Dohme LLC NCT04976634

Активно (без набиране) Фаза 2

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Follicular Lymphoma

This single-arm phase II interventional study aims to assess disease response to, and toxicity of, a combination of obinutuzumab and atezolizumab, with or without radiotherapy, in treatment naive Follicular Lymphoma. The study will involve an induction phase and a maintenance phase for responding participants, for up to 24 months. Response to treatment will be monitored using medical imaging and clinical assessment.

Начало: 17.08.2021 Край: 01.07.2025 Възраст: от 18 г. Лечение

Australia Olivia Newton-John Cancer Research Institute NCT04962126

Активно (без набиране) Фаза 3

The Cryopreserved vs. Liquid Platelets Trial

Surgical Blood Loss Hemorrhage

This trial is a phase III multicentre blinded randomised controlled clinical non-inferiority trial of cryopreserved platelets vs. conventional liquid-stored platelets for the management of surgical bleeding. The aim of the study is to assess the efficacy, safety and cost effectiveness of cryopreserved platelets, compared to conventional liquid-stored platelets, for the management of surgical bleeding. This trial will recruit cardiac surgical patients deemed to be at high risk of surgical bleeding and who may potentially require transfusion of platelets. It is estimated to require 808 high-risk cardiac surgical patients to be recruited, to obtain 202 patients who receive transfused study platelets for surgical bleeding.

Начало: 17.08.2021 Край: 01.11.2025 Лечение

Australia Australian and New Zealand Intensive Care Research Cent NCT03991481

Активно (без набиране) Фаза 3

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Начало: 16.08.2021 Край: 23.12.2026 Възраст: 12–75 г. Лечение

Australia, Brazil, Canada +2 Akeso NCT04974398

Активно (без набиране) Фаза 3

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled. All eligible participants will initially receive open label tofacitinib at a dose expected to produce equivalent systemic exposure to that observed in adults receiving 5 mg BID with the option for individual dose increase to 10 mg BID adult dose equivalent if dose escalation criteria are met. The primary objective of this study is to evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active UC. The primary endpoint is remission by central read Mayo score following 44 weeks in the maintenance phase. Remission is defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The study Design is an open-label Phase 3 study that includes a screening period of up to 4-weeks duration, an 8-week or 16-week induction phase, a 44-week maintenance phase, and a 24-month extension phase for pediatric participants with moderately to severely active UC. Participants will have a follow-up visit 4 weeks after the last dose of study intervention and a telephone contact 8 weeks later to assess for any adverse events (AEs)/serious adverse events (SAEs). The total maximum duration of this study will be up to 180 weeks.

Начало: 12.08.2021 Край: 18.07.2029 Възраст: 2–17 г. Лечение

Australia, Belgium, Canada +13 Pfizer NCT04624230

Активно (без набиране) Фаза 3

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma Progressive Brain Metastasis

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive brain metastasis or adolescents with or without new progressive brain metastasis receive HBI-8000 combined with nivolumab.

Начало: 12.08.2021 Край: 01.12.2026 Възраст: от 12 г. Лечение

Australia, Belgium, Brazil +13 HUYABIO International, LLC. NCT04674683

Активно (без набиране) Фаза 1

Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury

Lung Injury

Phase 1 study investigating safety of lanadelumab administration to patients with lung injury

Начало: 09.08.2021 Край: 01.12.2024 Възраст: 18–90 г. Лечение

Australia St Vincent's Institute of Medical Research NCT04848272

Активно (без набиране) Фаза 1

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Solid Tumor, Adult Non-small Cell Lung Cancer Melanoma

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

Начало: 04.08.2021 Край: 30.03.2029 Възраст: от 18 г. Лечение

Australia, China, France +4 Pierre Fabre Medicament NCT04913285

1 … 124 125 126 127 128 … 154